During CNS drug development the pharmaceutical industry relies heavily on having objective evidence for intervention effects. EEG is increasingly included to provide this evidence. Traditionally, EEG analysis has focused on the spectral features of the EEG, thereby missing information in the temporal and spatial domain. Using only spectral features means that drug-induced effects on brain activity may be overlooked. Consequently, the insights can be inconclusive or even wrong, leading to incorrect decision making during drug development. In contrast, the Neurophysiological Biomarker Toolbox (NBT) provides comprehensive mapping and integration of biomarkers based on the EEG, resulting in accurate indices of drug effects on the brain, which are urgently needed in the pharmaceutical industry.